Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α–Based Regimens

Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)– and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV therapy in previously untreated patients and c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Muir, A J, Gong, L, Johnson, S G, Lee, M T M, Williams, M S, Klein, T E, Caudle, K E, Nelson, D R
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2014
Matèries:
CPIC Guidelines
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3904555/
https://ncbi.nlm.nih.gov/pubmed/24096968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/clpt.2013.203
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars